We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novo Nordisk (NVO) Stock Declines While Market Improves: Some Information for Investors
Read MoreHide Full Article
Novo Nordisk (NVO - Free Report) closed the most recent trading day at $38.70, moving -1.11% from the previous trading session. The stock fell short of the S&P 500, which registered a gain of 0.6% for the day. Meanwhile, the Dow gained 0.03%, and the Nasdaq, a tech-heavy index, added 1.18%.
The drugmaker's stock has climbed by 1.09% in the past month, falling short of the Medical sector's gain of 2.23% and outpacing the S&P 500's loss of 0.79%.
The investment community will be paying close attention to the earnings performance of Novo Nordisk in its upcoming release. The company is slated to reveal its earnings on November 4, 2026. The company is predicted to post an EPS of $0.81, indicating a 20.59% decline compared to the equivalent quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $11.39 billion, down 3.03% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates are projecting earnings of $3.42 per share and revenue of $45.66 billion, which would represent changes of -13.64% and -2.38%, respectively, from the prior year.
Any recent changes to analyst estimates for Novo Nordisk should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 3.48% lower. Right now, Novo Nordisk possesses a Zacks Rank of #3 (Hold).
Looking at its valuation, Novo Nordisk is holding a Forward P/E ratio of 11.45. This expresses a discount compared to the average Forward P/E of 17.26 of its industry.
We can additionally observe that NVO currently boasts a PEG ratio of 1.33. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.02 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 218, which puts it in the bottom 12% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Novo Nordisk (NVO) Stock Declines While Market Improves: Some Information for Investors
Novo Nordisk (NVO - Free Report) closed the most recent trading day at $38.70, moving -1.11% from the previous trading session. The stock fell short of the S&P 500, which registered a gain of 0.6% for the day. Meanwhile, the Dow gained 0.03%, and the Nasdaq, a tech-heavy index, added 1.18%.
The drugmaker's stock has climbed by 1.09% in the past month, falling short of the Medical sector's gain of 2.23% and outpacing the S&P 500's loss of 0.79%.
The investment community will be paying close attention to the earnings performance of Novo Nordisk in its upcoming release. The company is slated to reveal its earnings on November 4, 2026. The company is predicted to post an EPS of $0.81, indicating a 20.59% decline compared to the equivalent quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $11.39 billion, down 3.03% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates are projecting earnings of $3.42 per share and revenue of $45.66 billion, which would represent changes of -13.64% and -2.38%, respectively, from the prior year.
Any recent changes to analyst estimates for Novo Nordisk should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 3.48% lower. Right now, Novo Nordisk possesses a Zacks Rank of #3 (Hold).
Looking at its valuation, Novo Nordisk is holding a Forward P/E ratio of 11.45. This expresses a discount compared to the average Forward P/E of 17.26 of its industry.
We can additionally observe that NVO currently boasts a PEG ratio of 1.33. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.02 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 218, which puts it in the bottom 12% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.